首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1140675

2022-2029 年全球豬瘟 (CSF) 疫苗市場

Global Classical Swine Fever Vaccines Market - 2022-2029

出版日期: 2022年10月20日 | 出版商:

DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

在預測期內，新動物疫苗的推出將繼續支持市場增長。

獸用疫苗可改善伴侶動物的健康，防止家畜和野生動物在動物之間傳播疾病和傳染病。因此，動物保健公司正在開發新的動物疫苗。市場增長的主要驅動力之一是動物疫苗製造商推出的新動物疫苗的數量。2020 年 5 月，Indian Immunologicals Limited（IIL）推出了品牌名稱為“Raksha Class”的經典豬瘟 (CSF) 疫苗。該疫苗是與Bareilly的印度獸醫研究所 (IVRI) 合作開發的。

此外，豬瘟的不斷研發正在推動全球豬瘟市場的增長。豬瘟又稱豬瘟，是一種豬的傳染性病毒性疾病，包括野豬。屬於黃病毒科瘟病毒屬的結合病毒，與牛病毒性腹瀉和臨界疾病密切相關。它導致包括印度在內的幾個國家的豬死亡率很高。印度自 1964 年以來一直在使用英國開發的豬瘟 (CSF) 疫苗，但由於印度飼養的豬數量不斷增加，因此鼓勵開發本地生產的豬瘟 (CSF) 疫苗。我們是。

此外，養豬者對疫苗接種意識的提高正在推動全球市場的增長。接種疫苗是控制豬群疾病的必要措施。豬疫苗旨在減少易感動物的數量、臨床疾病和病原體的傳播。豬疫苗可以保護豬免受傳染病的侵害，其中主動和被動免疫是保護自己免受疾病侵害的方法。根據豬健康信息中心 (SWIC) 的說法，豬特斯科病毒 (PTV) 是小核糖核酸病毒科特斯科病毒屬的一種無包膜 RNA 病毒。已知大約有 13 種 PTV 血清型，其中 PTV-1 與 Tescovirus 腦脊髓炎有關。PTV-2、PTV-3 和 PTV-5 與塔凡病有關。豬的 PTV 感染可能是亞臨床的。

然而，嚴格的監管政策正在抑制全球豬瘟（CSF）疫苗市場的增長。批准和許可動物疫苗接種需要各種法規和政策。每個國家都有監管機構制定動物疫苗接種的標準和協議。例如，美國農業部下屬的動植物衛生檢驗局 (APHIS) 的獸醫生物製品中心 (CVB) 負責監管美國疫苗的生產和銷售。獸藥公司必須獲得 CVB 法規授予的產品許可證和設施許可證。這些許可證是在經過檢查的設施和適當的條件下授予的。CVB 要求所有產品都經過批准程序，以確保它們符合 1913 年病毒血清毒素法案中規定的四個特徵（純度、效力、安全性和有效性）。

地理滲透：

北美是預測期內的主要地區。

北美在全球豬瘟 (CSF) 疫苗市場上佔據主導地位，預計在預測期內將保持其地位。在預測期內，美國在北美豬瘟 (CSF) 疫苗市場的市場份額最高。發達的醫療基礎設施和用於開發針對各種疾病的新型疫苗的巨額研發支出是支持該地區豬瘟 (CSF) 疫苗市場增長的因素之一。

歐洲在全球豬瘟（CSF）疫苗市場上佔據第二主導地位。豬肉的高消費是推動該地區市場增長的主要因素之一。西班牙在歐洲豬肉產業中佔有重要份額。由於養豬場眾多，豬肉生產主要集中在該國西部地區。豬肉行業邊際聚落的擴大也是導致豬肉養殖市場集中的主要因素之一。西班牙佔歐洲生豬的 24%。

據估計，在預測期內，亞太地區的豬瘟 (CSF) 疫苗市場將以顯著的增長率增長。這種增長歸因於有效疫苗的研究和開發的增加。例如，2020 年 2 月，印度科學家在印度研製出一種新的疫苗來控制經典豬瘟。該疫苗將有助於生產一種有效的石膏替代品，以替代目前使用的疫苗，以預防佔該國肉類總產量 10% 的豬致命發燒。

競爭格局：

豬瘟（CSF）疫苗市場是一個競爭激烈的市場。對全球市場增長做出貢獻的主要豬瘟（CSF）疫苗公司是Panav Biotech、Boehringer Ingelheim International GmbH、Ceva、Bioveta、a.s.、Indian Immunologicals Limited、Qilu Animal Health Products Co, Ltd.。主要參與者正在為豬瘟 (CSF) 疫苗市場的全球增長採用新產品發布和擴張戰略。幾家主要參與者已在市場上推出新產品以擴大其產品組合。2020年6月，勃林格殷格翰推出中國自主研發的豬瘟（CSF）疫苗，並獲得中國農業農村部頒發的《新獸藥註冊證》。據說這是首個跨國公司與中國科研院所聯合研製的豬瘟活疫苗。一些主要參與者正在遵循併購策略來擴展業務。例如，2021 年 12 月，勃林格殷格翰將收購 Labor Dr. Merk & Kollegen，以加強其下一代免疫腫瘤學項目。此次收購擴大並加速了基於 ATMP 的免疫腫瘤藥物開發的綜合計劃，包括具有修飾糖蛋白 (GP) 平台的水泡性口炎病毒 (VSV) 和癌症疫苗平台。

COVID-19 的影響對全球經典豬瘟 (CSF) 疫苗市場產生了負面影響。

COVID-19 的爆發無疑影響了全球豬瘟 (CSF) 疫苗市場。因為封鎖迫使全球豬瘟（CSF）疫苗供應。研究人員將重點轉移到開發 COVID-19 疫苗上，這阻礙了豬瘟 (CSF) 疫苗的研發。因此，預計 2020 年豬瘟（CSF）疫苗市場將出現大幅下滑。

Market Overview

Classical Swine Fever Vaccines Market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 7.5 % during the forecast period (2022-2029).

Classical swine fever is a contagious and economically significant viral disease of pigs. The severity of the illness varies with the strain of the virus, the pig's age, and the herd's immune status. Classical swine fever is related to the virus of bovine virus diarrhea (BVD) and sheep's border disease (BD). Suvaxyn CSF Marker is a veterinary vaccine that protects pigs against outbreaks of classical swine fever. It also protects breeding sows to reduce infection of their unborn piglets by classical swine fever virus. This vaccine contains live bovine viral diarrhea virus (BVDV), which has been modified to replace the envelope (E2) gene of BVDV with the corresponding gene of CSFV. The rising prevalence of awareness regarding the classical swine fever vaccines and the increasing consumption of pork meat are some factors that are expected to propel market growth. Moreover, the introduction of new veterinary vaccines by animal health companies is further supporting the growth of the market across the globe.

Market Dynamics: The introduction of a new veterinary vaccine will continue supporting the market's growth during the forecast period.

Veterinary vaccines improve companion animals' health and prevent animal-to-human transmission of diseases and infections from domestic animals and wildlife. It has led to the development of new veterinary vaccines by animal health companies. One of the major factors augmenting the market's growth includes the number of new veterinary vaccines introduced by veterinary vaccine manufacturers. In May 2020, Indian Immunologicals Limited (IIL) launched the Classical Swine Fever (CSF) vaccine under the brand name 'Raksha Class .'This vaccine was developed in collaboration with the Indian Veterinary Research Institute (IVRI), Bareilly.

Also, Continuous R&D in the field of swine fever is driving the growth of the global classical swine fever market. Classical swine fever (CSF), also termed hog cholera, is an infectious viral disease of pigs, including wild boar. The connective virus is a member of the Flaviviridae's genus Pestivirus family and is intimately connected to bovine viral diarrhea and border disease. It leads to the high fatality of pigs across several countries, including India. The country has been using the UK-developed classical swine fever vaccine since 1964; however, the country is developing a locally manufactured classical swine fever vaccine for the increasing pig population in India.

Moreover, increasing awareness of the vaccination of swineherds is driving the growth of the global market. Vaccination is a necessary tool for controlling diseases in swine herds. The swine vaccine is designed to reduce the number of susceptible animals, clinical diseases, and pathogen spread. The swine vaccine prevents swine from contagious diseases, in which active and passive immunity are methods to protect against disease. According to the Swine Health Information Center (SWIC), Porcine teschovirus (PTV) is a non-enveloped RNA virus in the genusTeschovirus and the family Picornaviridae. There are about 13 known PTV serotypes in which the PTV-1 is linked with teschovirus encephalomyelitis. PTV-2, PTV -3, and PTV -5 are linked with Talfan disease. The PTV infection in swine may be subclinical.

However, stringent regulatory policies are restraining the growth of the global classical swine fever vaccine market. Various regulations and policies are required to approve and authorize animal vaccination. Each country has its regulatory organizations that set the standards and protocols for animal vaccination. For instance, the Center for Veterinary Biologics (CVB) in the Animal and Plant Health Inspection Service (APHIS), a USDA branch, regulates vaccine production and marketing in the US. The animal health companies must have both a product license and an establishment license granted by the CVB rules. These licenses are given under some conditions such as inspected facilities and appropriate. The CVB requires all products to undergo an approval process to ensure compliance with the four characteristics outlined in the Virus-Serum-Toxin Act of 1913, including purity, potency, safety, and efficacy.

Market Segmentation: Government tender segment accounted for the highest share in global classical swine fever vaccines market.

The government tender segment held a major share in the classical swine fever vaccines market in the forecast year. The government has a huge focus on containing the spread of classical swine fever, owing to which the government tender is scheduled for the sales of the classical swine fever vaccine. Moreover, the more effective vaccine in government organizations or private organizations under the government's supervision is further expected to contribute to the segment's growth during the forecast period.

The classical swine fever vaccine market has been classified into tissue culture origin and cell line origin based on the type. The tissue culture origin segment accounted for a significant market share in the global classical swine fever vaccine market. Tissue culture origin dominated the classical swine fever vaccines market in the forecast period. Cell culture is widely used in the US biopharmaceutical industries for vaccine production, drug development, and tissue culture. Tissue culture has a huge significance in the classical swine fever vaccine; therefore, considerable growth can be projected in the segment during the forecast period.

Geographical Penetration: North America is the dominating region during the forecast period.

North America dominated the global classical swine fever vaccines market and is expected to retain its position during the forecast period. The US contributed the highest market share in the North American classical swine fever vaccines market in the forecast period. The well-developed healthcare infrastructure and the huge spending on R&D for the development of novel vaccines for a range of diseases are some factors supporting the growth of the classical swine fever vaccines market in the region.

Europe holds a second dominant position in the global classical swine fever vaccines market. The high consumption of pork meat is one of the major factors that drive the market growth in the region. Spain comprises a significant share of the pork industry in Europe. Pork production is mainly accounted for in western parts of the country due to substantial pork breeding farms. Growing marginalization in the pork industry is also one of the major factors contributing to pork husbandry's concentrated market. Spain accounted for 24% of Europe's pigs.

The Asia Pacific is estimated to grow at a considerable growth rate in the classical swine fever vaccines market during the forecast period. This growth can be accredited to the rising R&D for an effective vaccine. For instance, in February 2020, Indian Scientists developed a new vaccine in India to control classical swine fever. This vaccine helps in producing an effective cast alternative to currently used vaccines for preventing the deadly fever in pigs that contribute to 10 % of the country's total meat production.

Competitive Landscape:

The classical swine fever vaccine market is highly competitive. The key classical swine fever vaccine players contributing to the global market's growth include Panav Biotech, Boehringer Ingelheim International GmbH, Ceva, Bioveta, a.s., Indian Immunologicals Limited, and Qilu Animal Health Products Co., Ltd. among others. The major players are adopting new product launches and expansion strategies for global growth in the classical swine fever vaccines market. Some key players launched a new product in the market to expand their product portfolio. In June 2020, Boehringer Ingelheim announced the China-developed classical swine fever vaccine and obtained a "New veterinary drug registration certificate" from the Ministry of Agriculture and Rural Affairs of China. It is regarded as the first classical swine fever live vaccine jointly developed by a multinational company and Chinese research institutes. Some key players follow merger and acquisition strategies to expand their business. For instance, in December 2021, Boehringer Ingelheim to Acquired Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program. This acquisition helped to expand and accelerate its comprehensive program for the development of ATMP-based immuno-oncology therapies, including the Vesicular Stomatitis Virus (VSV) with modified glycoprotein (GP) platform and cancer vaccine platforms.

COVID-19 Impact: Negative impact on the global classical swine fever vaccines market.

The outbreak of COVID-19 has certainly impacted the global classical swine fever vaccines market, as the lockdown has compelled the supply of classical swine fever vaccines across the globe. The researchers' shift in focus toward developing the COVID-19 vaccine has hampered the R&D in the classical swine fever vaccines. Therefore, the classical swine fever vaccine market is expected to foresee a considerable decline in 2020.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

3.1. Market Snippet by Type
3.2. Market Snippet by Application
3.3. Market Snippet by Region

4. Market Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising awareness about CSF in pig farmers
  - 4.1.1.2. Increasing demand for pork meat
- 4.1.2. Restraints:
  - 4.1.2.1. Lack of medical freezers to store vaccine
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Value Chain Analysis
5.4. PEST Analysis
5.5. Pricing Analysis
5.6. Regulatory Analysis
5.7. Reimbursement Analysis
5.8. Unmet Needs
5.9. Patent Trends

6. COVID-19 Analysis

6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Type

7.1. Introduction
7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
7.3. Market Attractiveness Index, By Type Segment
- 7.3.1. Tissue Culture Origin*
  - 7.3.1.1. Introduction
  - 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
- 7.3.2. Cell Line Origin

8. By Application

8.1. Introduction
8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
8.3. Market Attractiveness Index, By Application Segment
- 8.3.1. Government Tender*
  - 8.3.1.1. Introduction
  - 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
- 8.3.2. Market Sales

9. By Region

9.1. Introduction
9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
9.3. Market Attractiveness Index, By Region
9.4. North America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.4.5.1. The U.S.
  - 9.4.5.2. Canada
  - 9.4.5.3. Mexico
9.5. Europe
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.5.5.1. Germany
  - 9.5.5.2. The U.K.
  - 9.5.5.3. France
  - 9.5.5.4. Italy
  - 9.5.5.5. Spain
  - 9.5.5.6. Rest of Europe
9.6. South America
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.6.5.1. Brazil
  - 9.6.5.2. Argentina
  - 9.6.5.3. Rest of South America
9.7. Asia Pacific
- 9.7.1. Introduction
- 9.7.2. Key Region-Specific Dynamics
- 9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.7.5.1. China
  - 9.7.5.2. India
  - 9.7.5.3. Japan
  - 9.7.5.4. Australia
  - 9.7.5.5. Rest of Asia Pacific
9.8. The Middle East and Africa
- 9.8.1. Introduction
- 9.8.2. Key Region-Specific Dynamics
- 9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Boehringer Ingelheim International GmbH*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Key Highlights
- 11.1.4. Financial Overview
11.2. Panav Bio-tech
11.3. Ceva
11.4. Bioveta, a.s.
11.5. Indian Immunologicals Limited
11.6. Qilu Animal Health Products Co., Ltd.
11.7. Tianjin Ruipu Biotechnology Co., Ltd.
11.8. Merck & Co., Inc.(*LIST NOT EXHAUSTIVE)